Anika Therapeutics, Inc.

Anika Therapeutics, Inc. is a global leader in OA Pain Management and regenerative solutions, focusing on early intervention orthopedics. Founded in 1992, the company uses its proprietary hyaluronic acid (HA) technology to develop differentiated products. Anika's mission is to restore active living, empower surgeon choice, and enhance patient outcomes worldwide, driven by partnerships with physicians. In October 2024, Anika announced a strategic shift to concentrate on its OA Pain Management and Regenerative Solutions portfolios. This involved the sale of Arthrosurface Incorporated on October 31, 2024, and the sale of Parcus Medical, LLC on March 7, 2025. Both entities were acquired in early 2020. The company's focused strategy emphasizes HA-based products to address unmet needs in growing markets. Anika is particularly focused on the commercial execution and adoption of its newest product in the Regenerative Solutions portfolio, the Integrity Implant System ("Integrity"). Integrity is an HA-based scaffold designed for rotator cuff and other tendon repairs, and has shown strong performance with continued growth in surgeries and significant adoption by new customers. Anika plans to continue investing in its Regenerative Solutions R&D pipeline in preparation for potential U.S. approval and launch of Hyalofast and Cingal, each representing an incremental U.S. addressable market of at least $1 billion.